HENDERSON, Nev. and BAD WILDUNGEN, Germany, July 23, 2007 (PRIME NEWSWIRE) -- BodyTel Scientific Inc. (OTCBB:BDYT), a company focused on the development of innovative wireless healthcare products, today reported that it has begun the CE certification process for GlucoTel, a blood glucose monitoring device. The CE certification allows the company to market the GlucoTel monitoring device within the European Union and other countries using this standard. In order to assist in this certification process, CSL Cambridge Sensors Limited (www.cs-limited.co.uk), a designer and manufacturer of test strips for use in blood glucose test systems, has been retained.
The GlucoTel monitoring device is part of a self-managed telemedical diabetes system. It supports patients and doctors with the treatment of diabetes and its resulting illnesses. The blood sugar measuring instrument determines the glucose level electronically and transmits it automatically via Bluetooth to the patient's mobile phone. The data is then directly sent per SMS (text message) or GPRS (data package) to an Internet database and stored long-term.
BodyTel has started the certification process with the CE approval agency Lloyds Registration Quality Assurance (www.lrqa.de), a German division of Lloyds Register Group. In order to receive the CE designation, the agency must review BodyTel's compliance with the ISO norm 13485. It is anticipated that the finalizing of the CE audit will take place by the end of the summer.
Stefan Schraps, CEO of BodyTel Scientific, commented, "Obtaining the CE approval will be a significant milestone for our company in our efforts to make the GlucoTel system commercially available. It is expected that with the CE certification, we will begin marketing GlucoTel within Europe and beyond before the end of the year."
About BodyTel Scientific
BodyTel Scientific Inc. is a company focused on the development of innovative wireless health monitoring products. Please visit www.bodytel.com for more company information.
Forward-Looking Statements
Statements regarding the Company's business which are not historical facts are `forward-looking statements' that involve risks and uncertainties that could cause actual results to differ materially from the potential results discussed in the forward-looking statements. Forward-looking statements in this press release include that; it is anticipated that the finalising of the CE audit will take place by the end of the summer, Obtaining the CE approval will be a significant milestone for our company in our efforts to make the GlucoTel system commercially available. It is expected that with the CE certification, we will begin marketing GlucoTel within Europe and beyond before the end of the year. Actual results may differ materially from those currently anticipated due to a number of factors as we may find that our products must compete with cheaper or better products; we may not be able to retain key employees; a bigger market may not develop for our products and we may not be able to continue to attract new customers; we may face litigation if our technology fails to work when required; our intellectual property may be attacked and defeated in court proceedings; our patent and FDA/CE filings may be rejected by the patent offices and regulators; other companies may discover and develop better or cheaper technologies that would render our products obsolete and we may not have sufficient funding to further develop and/or market our technology. Readers are directed to BodyTel Scientific, Inc.'s reports as filed with the U.S. Securities and Exchange Commission from time to time, including but not limited to its 8-K filed December 14, 2006 under our prior name Sellcell.net which outlined the company's current business, for further information and factors that may affect BodyTel Scientific Inc.'s business and results of operations as well as the Company's form 10-KSB filed on December 15, 2006 and the Company's form 10-QSB filed on January 16, 2007. BodyTel Scientific Inc. undertakes no obligations to publicly update any forward-looking statements to reflect future events or circumstances.